China’s Pharmaceutical Innovation Goes Global: Challenges and New Momentum In the first five months of 2025, China’s outbound innovative drug licensing deals have exceeded USD 45 billion, almost equaling the total for all of 2024.…
On May 6, the U.S. government announced plans to unveil new pharmaceutical tariff measures within the next two weeks. Can innovative drugs accelerate overseas expansion by 2025? Under current U.S. policy, pharmaceuticals are classified as…
In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion, marking a 40% year-over-year increase. Antibody-drug conjugates (ADCs) and bispecific antibodies now account for over 60% of all outbound transactions…
Guangdong, China — May 22, 2025 丨 The National Medical Products Administration (NMPA) has officially approved Onradivir Tablets, a Class 1 innovative drug developed by Guangdong Raynovent Biotechnology Co., Ltd. for the treatment of adult…
On July 3, 2025, Simcere Pharmaceutical Group Limited’s innovative drug subsidiary, Simcere, announced that its next-generation VEGF-targeting antibody, Suvemcitug Injection, had received marketing approval from the National Medical Products Administration (NMPA). Suvemcitug is the first…
Recently, the National Medical Products Administration (NMPA) granted conditional approval for Olgotrelvir Sodium Capsules, a Class I innovative drug developed by Zhejiang ACEA Pharmaceutical Co., Ltd. ✨ The drug represents the world’s first dual-target oral…
The National Medical Products Administration (NMPA) has officially approved Firsekibart Injection, a Class 1 innovative biologic drug independently developed by Changchun GeneScience Pharmaceuticals Co., Ltd. ✨ This approval marks a major milestone in China’s treatment…
Nanjing Zenshine Pharmaceutical Co., Ltd. has announced that its independently developed antiviral drug, Sebaloxavir Marboxil tablets, has officially been approved for marketing by China’s National Medical Products Administration (NMPA). This approval marks a major milestone…
Suzhou Ascentage Pharma has achieved a significant milestone with the conditional approval of Lisaftoclax Tablets (brand name: Lishengtuo, research code: APG-2575) by the National Medical Products Administration (NMPA). ✨ This approval is for the treatment…
The National Medical Products Administration (NMPA) of China has granted conditional approval for Ifupinostat Hydrochloride for Injection (brand name: Beitelin), developed by Guangzhou BeBetter Medicine Co., Ltd. This Class 1 innovative drug is approved as…
The National Medical Products Administration (NMPA) has officially approved Zeprumetostat Tablets (brand name: Airuijing, development code: SHR2554), a Class 1 innovative drug independently developed by Jiangsu Hengrui Pharmaceuticals. ✨ The approval covers the treatment of…
As Artificial Intelligence (AI) continues to evolve, the global pharmaceutical industry is undergoing a profound transformation. AI is redefining innovative drug development and reshaping the pharmaceutical supply chain—from target identification to intelligent distribution ✨AI in…
